Breaking New Ground in ALK Inhibitors: Recent Advances and Emerging Trends in the Anaplastic Lymphoma Kinase Market
Introduction Anaplastic Lymphoma Kinase (ALK) inhibitors have dramatically reshaped the landscape of cancer treatment, especially for non-small cell lung cancer (NSCLC) patients with ALK gene rearrangements. This segment, driven by … Read More